The inhibition of MDH1, a key enzyme in the glutamine catabolic pathway, has been recently reported to sensitize cancer cells to oxidative stress, decreasing cell proliferation and inhibiting tumor growth in vivo [31], and its targeting is being suggested as a therapeutic approach [32]. Here, MDH1 is linked to neoplasm.